Ultragenyx Pharma (RARE) Misses Q3 EPS by 11c
Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.64), $0.11 worse than the analyst estimate of ($1.53).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.64), $0.11 worse than the analyst estimate of ($1.53).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.